A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV).

Trial Profile

A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2012

At a glance

  • Drugs Candesartan cilexetil; Olmesartan medoxomil
  • Indications Heart failure
  • Focus Pharmacodynamics
  • Acronyms OLMEBNP
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Aug 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Sep 2008 Actual start date added (Jun 2008) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top